Published : Jun-2020
No. of Pages : 129
1.1 List of Tables
1.2 List of Figures
2 Transthyretin Amyloidosis: Executive Summary
2.1 The ATTR Market Will See Dramatic Increases In Patient Population and Approved Therapies From 2019 to 2029
2.2 Multi-Label Drug Approvals Within ATTR Will Fuel Company Revenues
2.3 Rising Patient Populations and a Strong Pipeline Will Bring Considerable Growth to the ATTR Market Over the Forecast Period
2.4 RNAi Therapies Will Dominate the ATTR Market During the Forecast Period
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
5 Epidemiology
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan
7 Competitive Assessment
7.1 Overview
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Increased Awareness and Improved Diagnosis
8.3 Novel Treatments in ATTR Cardiomyopathy
8.4 Treatment Guidelines and Lines of Therapy
8.5 Treatments for Advanced Disease
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Pfizer's Portfolio Assessment
10.4 Alnylam's Portfolio Assessment
10.5 AKCEA's Portfolio Assessment
10.6 Eidos' Portfolio Assessment
10.7 Proclara and Prothena
11 Market Outlook
12 Appendix
List of Tables
Table 1: Transthyretin Amyloidosis: Key Metrics in the 7MM
Table 2: Classification of Amyloidosis Stages
Table 3: Coutinho's Staging System
Table 4: Risk Factors and Comorbidities for Amyloidosis
Table 5: Country Profile - US
Table 6: Country Profile - 5EU
Table 7: Country Profile - Japan
Table 8: Leading Treatments for ATTR, 2020
Table 9: Pfizer's Amyloidosis Portfolio Assessment, 2020
Table 10: Alnylam's Amyloidosis Portfolio Assessment, 2020
Table 11: AKCEA's Amyloidosis Portfolio Assessment, 2020
Table 12: Eidos' Amyloidosis Portfolio Assessment, 2020
Table 13: ATTR Market - Global Drivers and Barriers, 2019-2029
Table 14: Key Events Impacting Sales for ATTR in the US, 2019-2029
Table 15: ATTR Market - Global Drivers and Barriers in the US, 2019-2029
Table 16: Key Events Impacting Sales for ATTR in the 5EU, 2019-2029
Table 17: ATTR Market - Global Drivers and Barriers in the 5EU, 2019-2029
Table 18: Key Events Impacting Sales for ATTR in Japan, 2019-2029
Table 19: ATTR Market - Global Drivers and Barriers in Japan, 2019-2029
Table 20: Key Historical and Projected Launch Dates for ATTR
Table 21: Key Historical and Projected Patent Expiry Dates for ATTR
Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales for ATTR by Country, 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in ATTR During the Forecast Period
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in ATTR, 2019-2029
Figure 4: Mechanisms of AL and ATTR
Figure 5: 7MM, Diagnosed Prevalence of AL Amyloidosis, Men and Women, All Ages, 2019
Figure 6: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of AL Amyloidosis
Figure 7: 7MM, Sources Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of AL Amyloidosis by Types
Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AL Amyloidosis
Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AL Amyloidosis by Mayo Classification Stages
Figure 10: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AL Amyloidosis with Previous Diagnosis of Multiple Myeloma
Figure 11: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of ATTR-h
Figure 12: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of ATTR-h, ATTR-wt, and AA Amyloidosis
Figure 13: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of ATTR-h Underwent Liver Transplantation
Figure 14: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of ATTR-wt and AA Amyloidosis
Figure 15: 7MM, Diagnosed Incident Cases of AL Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 16: 7MM, Diagnosed Incident Cases of AL Amyloidosis, by Sex, All Ages, N, 2019
Figure 17: 7MM, Diagnosed Incident Cases of AL Amyloidosis by Age, Both Sexes, N, 2019
Figure 18: 7MM, Diagnosed Incident Cases of AL Amyloidosis by Subtypes, All Ages, Both Sexes, N, 2019
Figure 19: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 20: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis, by Sex, All Ages, N, 2019
Figure 21: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis by Age, Both Sexes, N, 2019
Figure 22: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis by Types, All Ages, Both Sexes, N, 2019
Figure 23: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis by Mayo Classification Stages, All Ages, Both Sexes, N, 2019
Figure 24: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis with Previous Diagnosis of Multiple Myeloma, All Ages, Both Sexes, N, 2019
Figure 25: 7MM, Diagnosed Incident Cases of ATTR-h, Both Sexes, All Ages, N, 2019
Figure 26: 7MM, Diagnosed Prevalent Cases of ATTR-h, Both Sexes, All Ages, N, 2019
Figure 27: 7MM, Diagnosed Prevalent Cases of ATTR-h Who Underwent Liver Transplantation, All Ages, Both Sexes, N, 2019
Figure 28: 7MM, Diagnosed Incident Cases of ATTR-wt, Both Sexes, All Ages, N, 2019
Figure 29: 7MM, Diagnosed Prevalent Cases of ATTR-wt, Both Sexes, All Ages, N, 2019
Figure 30: 7MM, Diagnosed Incident Cases of AA Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 31: 7MM, Diagnosed Prevalent Cases of AA Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 32: Red Flag Symptoms for ATTR-Associated Cardiomyopathy
Figure 33: Treatment Algorithm for ATTR
Figure 34: Unmet Needs and Opportunities in Transthyretin Amyloidosis
Figure 35: Overview of the Development Pipeline in ATTR
Figure 36: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for ATTR in the 7MM During the Forecast Period
Figure 37: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Approved for the Treatment of ATTR During the Forecast Period
Figure 38: Analysis of the Company Portfolio Gap in ATTR During the Forecast Period
Figure 39: Global (7MM) Sales Forecast by Country for ATTR in 2019 and 2029
Figure 40: Global (7MM) ATTR Sales Forecast by Drug in 2019 and 2029
Figure 41: Sales Forecast by Class for ATTR in the US in 2019 and 2029
Figure 42: Sales Forecast by Class for ATTR in the 5EU in 2019 and 2029
Figure 43: Sales Forecast by Class for ATTR in Japan in 2019 and 2029
